Current Report Filing (8-k)
September 12 2016 - 6:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): September 8, 2016
INTERCEPT PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-35668
|
|
22-3868459
|
(state or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
450 W. 15
th
Street, Suite
505
New York, New York
|
|
|
|
10011
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (646) 747-1000
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On September 8, 2016, the U.S. District
Court for the Southern District of New York (the “Court”) granted final approval of the previously announced agreement
with the lead plaintiff to settle the purported securities class action litigation, styled
In re: Intercept Pharmaceuticals,
Inc. Securities Litigation
, against Intercept Pharmaceuticals, Inc. (the “Company” or “Intercept”)
and certain of its officers.
The settlement included the payment of $55
million, of which $10 million was funded by the Company’s insurers.
The defendants
do not admit any liability as part of the settlement.
The final judgment and order of the Court
included a dismissal of the action with prejudice against all defendants.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
INTERCEPT PHARMACEUTICALS, INC.
|
|
|
|
|
Date: September 12, 2016
|
|
|
|
/s/ Mark Pruzanski
|
|
|
|
|
Mark Pruzanski, M.D.
President and Chief Executive Officer
|
|
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From Apr 2024 to May 2024
Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart
From May 2023 to May 2024